LHLeanne Hopkins

Leanne Hopkins

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Leanne Hopkins has a total of 64 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    The Scottish medicines in pregnancy programme: supporting the surveillance of medicines use during pregnancy and assessment of associated clinical outcomes

    by Tanja Mueller, Laura Stobo, Lynne Jarvis, Morven Millar, Emily Moore, Leanne Hopkins, Victoria Stark, Amy Hynd, Kwaku Osei-Oppong, Amanj Kurdi, et al.

    Purpose Pharmacological treatment during pregnancy is often necessary but presents challenges due to limited availability of safety data. In response to a UK-wide review of medicine safety, the Scottish Government commissioned the development of a national surveillance infrastructure to monitor medicines use during pregnancy and associated clinical outcomes. Methods Two real-world data assets were developed by integrating routinely collected primary and secondary care data: the Scottish Combined Medicines Dataset (SCoMeD) consolidates medicines data, while the Scottish Linked Pregnancy and Baby Dataset (SLiPBD) captures comprehensive data related to pregnancies. Two exemplar case studies were conducted to test the utility of these datasets. First, an audit of anti-seizure medicines (ASM) prescribing 04.2018–03.2025; and second, a retrospective cohort study of pregnancies conceived between 04.2010 and 06.2023, matching ASM exposed to ASM unexposed pregnancies to assess pregnancy, baby, and early childhood outcomes. Study periods were chosen based on data availability. Results The linkage of SCoMeD and SLiPBD enabled national-level surveillance of ASM prescribing trends and in-utero exposures. ASM prescribing surveillance showed an expected decrease in the use of valproate and topiramate among women of childbearing age, reflecting regulatory risk minimisation measures. Observational analyses confirmed valproate-associated teratogenic and developmental risks, whilst supporting the relative safety of lamotrigine and levetiracetam during pregnancy. Conclusions This programme demonstrates the value of leveraging nation-wide, whole system data for the surveillance of medicines safety in pregnancy. The linkage of real-world data provides regulatory-relevant evidence to inform guidelines and risk minimisation strategies. Scotland’s integrated medicines infrastructure positions the country as a key contributor in the European pharmacovigilance landscape.


  • Open Access

    Pregnancy, baby, and childhood outcomes from using anti-seizure medication during pregnancy

    by Emily Moore, Morven Millar, Rachel Merrick, Tanja Mueller, Victoria Stark, Lynne Jarvis, Amanj Kurdi, Leanne Hopkins, Stuart McTaggart, Rute Vieira, et al.

    Background Evidence of the safety of some anti-seizure medicines (ASMs) during pregnancy remains uncertain. Methods We conducted a population-based cohort study of singleton pregnancies in Scotland conceived between 01/04/2010-02/07/2023. Exposure was ‘any ASM’ prescription issued 28 days prior to conception up to pregnancy end. Seven monotherapies were also examined: valproate, topiramate, carbamazepine, lamotrigine, levetiracetam, gabapentin and pregabalin. Unexposed comparators were matched to the exposed on gestational age and year of conception. Pregnancy loss, congenital condition and child development outcomes were compared by exposure status using conditional logistic regression to account for the matched study design. Results Here we show pregnancy loss (3175/11,011 pregnancies, 28.8% vs. 24,040/107,889 pregnancies, 22.3%), congenital conditions (230/8370 babies, 2.7% vs. 1693/82,085 babies, 2.1%) and developmental concerns (1270/4890 live births, 26.0% vs. 7658/48,883 live births, 15.7%) are more common following any ASM exposure in pregnancy compared with no ASM exposure in pregnancy. Valproate is strongly associated with pregnancy loss (adjusted odds ratio (aOR): 1.92, 95% confidence interval (CI): 1.50-2.47), congenital conditions (aOR: 1.85, 95% CI: 1.06-3.21) and developmental concerns (aOR: 1.43, 95% CI: 1.01-2.03). Pregabalin, gabapentin and any ASM are also associated with pregnancy loss and developmental concerns. Conclusions Our findings corroborate the associated risks of valproate use and embryo malformations, support the use of lamotrigine and levetiracetam in pregnancy and raise concerns regarding gabapentinoid use in pregnancy.


  • Open Access

    Anti-seizure medication in pregnancy and pregnancy, baby, and child outcomes: a population-based cohort study

    by Emily Moore, Morven Millar, Rachel Merrick, Tanja Mueller, Victoria Stark, Lynne Jarvis, Amanj Kurdi, Leanne Hopkins, Stuart McTaggart, Rute Vieira, et al.

    Background Evidence of the safety of some anti-seizure medicines (ASMs) during pregnancy remains uncertain. Methods We conducted a population-based cohort study of singleton pregnancies in Scotland conceived between 01/04/2010-02/07/2023. Exposure was ‘Any ASM’ dispensed 28 days prior to conception up to pregnancy end. Seven monotherapies were also examined: valproate, topiramate, carbamazepine, lamotrigine, levetiracetam, gabapentin, and pregabalin. Unexposed comparators were matched to the exposed on gestational age and year of conception. Pregnancy loss, congenital condition and child development outcomes were compared by exposure status using conditional logistic regression. Results Of 911,027 pregnancies, 11,011 (1.2%) were exposed to Any ASM. Pregnancy loss (3,175/11,011 pregnancies, 28.8% vs. 24,040/107,889 pregnancies, 22.3%), congenital conditions (230/8,370 babies, 2.7% vs. 1,693/82,085 babies, 2.1%) and developmental concerns (1,270/4,890 live births, 26.0% vs. 7,658/48,883 live births, 15.7%) were more common among Any ASM exposed vs. unexposed. Valproate was strongly associated with pregnancy loss (adjusted odds ratio (aOR): 1.92, 95% confidence interval (CI): 1.50–2.47), congenital conditions (aOR: 1.85, 95% CI: 1.06–3.21) and developmental concerns (aOR: 1.43, 95% CI: 1.01–2.03). Pregabalin, gabapentin and Any ASM were also associated with pregnancy loss and developmental concerns. Conclusions Our findings corroborate valproate teratogenicity, support the safety of lamotrigine and levetiracetam, and raise concerns regarding gabapentinoid use in pregnancy.

  • Open Access

    Data resource profile: Scottish Linked Pregnancy and Baby Dataset (SLiPBD)

    by Laura Lindsay, Kate Mark, Emily Moore, Jade Carruthers, Leanne Hopkins, Denise Jennings, Rachael Wood

    IntroductionHere we present the Scottish Linked Pregnancy and Baby Dataset (SLiPBD), a new national data resource held by Public Health Scotland (PHS). MethodsSLiPBD comprises a population-based e-cohort of all fetuses and births (babies) from pregnancies to women in Scotland from 2000 onwards. It is updated monthly by linking and reconciling the following national datasets: antenatal booking records; general and maternity hospital discharge records; termination of pregnancy notifications; and statutory live and stillbirth registrations. ResultsKey information included on all babies in SLiPBD includes estimated date of conception, end of pregnancy date, gestation, multiple pregnancy status, pregnancy outcome, and maternal sociodemographic characteristics. For live births, additional information on the birth, the baby's sociodemographic characteristics, and subsequent infant deaths is included. Following the cohort refresh in January 2024, SLiPBD contained 1,770,226 babies from 1,750,830 pregnancies to 898,161 women. Of the 1,770,226 babies, 1,284,461 (73%) were live births, 5,731 (0.3%) stillbirths, and 316,897 (18%) and 114,840 (6%) came from a pregnancy ending a termination or early spontaneous loss respectively. 22,414 (1%) had an unknown pregnancy outcome, and for 25,883 (1%) the pregnancy was still ongoing. Data completeness for key sociodemographic characteristics except for ethnicity was very high, and variables showed expected patterns. Ethnicity data completeness is poor on historical records but improving over time. Completeness of unique patient identifiers was very high. External validation to source datasets was reassuring. ConclusionSLiPBD can be analysed standalone or linked to other national vital event and health datasets held by PHS. It supports longitudinal and intergenerational analyses, enabling epidemiological and health service surveillance and research on maternal and child health. Researchers interested in accessing pseudonymised extracts of SLiPBD through the Scottish NHS safe haven facility should contact Research Data Scotland. PHS will continue to refine SLiPBD as source datasets improve. Key Features The Scottish Linked Pregnancy and Baby Dataset (SLiPBD) is a new national data resource created and maintained by Public Health Scotland to facilitate epidemiological and health service analyses focused on maternal and child health. SLiPBD comprises a population-based e-cohort of all fetuses and births (babies) from pregnancies to women in Scotland from 2000 onwards. At least 68,000 babies (of which at least 46,000 are live births) are included annually. SLiPBD is updated on a monthly basis by linking and reconciling records relating to ongoing and completed pregnancies from the following existing national datasets: antenatal booking records; general and maternity hospital discharge records; termination of pregnancy notifications; and statutory live and stillbirth registrations. Key information included on all babies in SLiPBD includes estimated date of conception, end of pregnancy date, gestation, multiple pregnancy status, pregnancy outcome, and maternal sociodemographic characteristics. For live births, additional information on the birth, the baby’s sociodemographic characteristics, and any subsequent infant deaths is included. Inclusion of unique personal identifiers for the mother and (where applicable) baby used within the health service and on statutory birth registration records ensures SLiPBD provides a core intergenerational spine record, allowing linkage between mothers and babies, and to other national datasets. Subject to governance approvals, researchers can access pseudonymised extracts of SLiPBD (linked to other national datasets as required) through the Scottish NHS safe haven facility, which is supported by Public Health Scotland. Interested researchers should submit an initial enquiry form to Research Data Scotland (https://www.researchdata.scot/accessing-data/).


  • Open Access

    Neonatal and maternal outcomes following SARS-CoV-2 infection and COVID-19 vaccination: a population-based matched cohort study

    by Laura Lindsay, Clara Calvert, Ting Shi, Jade Carruthers, Cheryl Denny, Jack Donaghy, Lisa E. M. Hopcroft, Leanne Hopkins, Anna Goulding, Terry McLaughlin, et al.

    Understanding the impact of SARS-CoV-2 infection and COVID-19 vaccination in pregnancy on neonatal and maternal outcomes informs clinical decision-making. Here we report a national, population-based, matched cohort study to investigate associations between SARS-CoV-2 infection and, separately, COVID-19 vaccination just before or during pregnancy and the risk of adverse neonatal and maternal outcomes among women in Scotland with a singleton pregnancy ending at ≥20 weeks gestation. Neonatal outcomes are stillbirth, neonatal death, extended perinatal mortality, preterm birth (overall, spontaneous, and provider-initiated), small-for-gestational age, and low Apgar score. Maternal outcomes are admission to critical care or death, venous thromboembolism, hypertensive disorders of pregnancy, and pregnancy-related bleeding. We use conditional logistic regression to derive odds ratios adjusted for socio-demographic and clinical characteristics (aORs). We find that infection is associated with an increased risk of preterm (aOR=1.36, 95% Confidence Interval [CI] = 1.16–1.59) and very preterm birth (aOR = 1.90, 95% CI 1.20–3.02), maternal admission to critical care or death (aOR=1.72, 95% CI = 1.39–2.12), and venous thromboembolism (aOR = 2.53, 95% CI = 1.47–4.35). We find no evidence of increased risk for any of our outcomes following vaccination. These data suggest SARS-CoV-2 infection during pregnancy is associated with adverse neonatal and maternal outcomes, and COVID-19 vaccination remains a safe way for pregnant women to protect themselves and their babies against infection.


  • Open Access

    A population-based matched cohort study of major congenital anomalies following COVID-19 vaccination and SARS-CoV-2 infection

    by Clara Calvert, Jade Carruthers, Cheryl Denny, Jack Donaghy, Lisa E. M. Hopcroft, Leanne Hopkins, Anna Goulding, Laura Lindsay, Terry McLaughlin, Emily Moore, et al.

    Evidence on associations between COVID-19 vaccination or SARS-CoV-2 infection and the risk of congenital anomalies is limited. Here we report a national, population-based, matched cohort study using linked electronic health records from Scotland (May 2020-April 2022) to estimate the association between COVID-19 vaccination and, separately, SARS-CoV-2 infection between six weeks pre-conception and 19 weeks and six days gestation and the risk of [1] any major congenital anomaly and [2] any non-genetic major congenital anomaly. Mothers vaccinated in this pregnancy exposure period mostly received an mRNA vaccine (73.7% Pfizer-BioNTech BNT162b2 and 7.9% Moderna mRNA-1273). Of the 6731 babies whose mothers were vaccinated in the pregnancy exposure period, 153 had any anomaly and 120 had a non-genetic anomaly. Primary analyses find no association between any vaccination and any anomaly (adjusted Odds Ratio [aOR] = 1.01, 95% Confidence Interval [CI] = 0.83-1.24) or non-genetic anomalies (aOR = 1.00, 95% CI = 0.81-1.22). Primary analyses also find no association between SARS-CoV-2 infection and any anomaly (aOR = 1.02, 95% CI = 0.66-1.60) or non-genetic anomalies (aOR = 0.94, 95% CI = 0.57-1.54). Findings are robust to sensitivity analyses. These data provide reassurance on the safety of vaccination, in particular mRNA vaccines, just before or in early pregnancy.


  • Open Access

    A population-based matched cohort study of early pregnancy outcomes following COVID-19 vaccination and SARS-CoV-2 infection

    by Clara Calvert, Jade Carruthers, Cheryl Denny, Jack Donaghy, Sam Hillman, Lisa E. M. Hopcroft, Leanne Hopkins, Anna Goulding, Laura Lindsay, Terry McLaughlin, et al.

    Data on the safety of COVID-19 vaccines in early pregnancy are limited. We conducted a national, population-based, matched cohort study assessing associations between COVID-19 vaccination and miscarriage prior to 20 weeks gestation and, separately, ectopic pregnancy. We identified women in Scotland vaccinated between 6 weeks preconception and 19 weeks 6 days gestation (for miscarriage; n = 18,780) or 2 weeks 6 days gestation (for ectopic; n = 10,570). Matched, unvaccinated women from the pre-pandemic and, separately, pandemic periods were used as controls. Here we show no association between vaccination and miscarriage (adjusted Odds Ratio [aOR], pre-pandemic controls = 1.02, 95% Confidence Interval [CI] = 0.96–1.09) or ectopic pregnancy (aOR = 1.13, 95% CI = 0.92–1.38). We undertook additional analyses examining confirmed SARS-CoV-2 infection as the exposure and similarly found no association with miscarriage or ectopic pregnancy. Our findings support current recommendations that vaccination remains the safest way for pregnant women to protect themselves and their babies from COVID-19.


  • Open Access

    COVID-19 vaccination and SARS-CoV-2 infection in early pregnancy and the risk of major congenital anomalies: a national population-based cohort study

    by Rachael Wood, Clara Calvert, Jade Carruthers, Cheryl Denny, Jack Donaghy, Lisa Hopcoft, Leanne Hopkins, Anna Goulding, Laura Lindsay, Terry McLaughlin, et al.

    Evidence on associations between COVID-19 vaccination or SARS-CoV-2 infection and the risk of congenital anomalies is limited. We conducted a national, population-based, matched cohort study to estimate the association between COVID-19 vaccination and, separately, SARS-CoV-2 infection between six weeks pre-conception and 19 weeks and six days gestation and the risk of [1] any congenital anomaly and; [2] non-genetic anomalies. Mothers vaccinated in this pregnancy exposure period mostly received an mRNA vaccine (73.7% Pfizer-BioNTech BNT162b2 and 7.9% Moderna mRNA-1273). Of the 6,731 babies whose mothers were vaccinated in the pregnancy exposure period, 153 had any congenital anomaly and 120 had a non-genetic anomaly. Primary analyses found no association between vaccination and any anomaly (adjusted Odds Ratio [aOR] = 1.01, 95% Confidence Interval [CI] = 0.83–1.24) or non-genetic anomalies (aOR = 1.00, 95% CI = 0.81–1.22). Primary analyses also found no association between SARS-CoV-2 infection and any anomaly (aOR = 1.02, 95% CI = 0.66–1.60) or non-genetic anomalies (aOR = 0.94, 95% CI = 0.57–1.54). Findings were robust to sensitivity analyses. These data provide reassurance on the safety of vaccination, in particular mRNA vaccines, just before or in early pregnancy.

  • Open Access

    COVID-19 in Pregnancy in Scotland (COPS): protocol for an observational study using linked Scottish national data

    by Sarah Jane Stock, David McAllister, Eleftheria Vasileiou, Colin R Simpson, Helen R Stagg, Utkarsh Agrawal, Colin McCowan, Leanne Hopkins, Jack Donaghy, Lewis Ritchie, et al.

    Introduction The effects of SARS-CoV-2 in pregnancy are not fully delineated. We will describe the incidence of COVID-19 in pregnancy at population level in Scotland, in a prospective cohort study using linked data. We will determine associations between COVID-19 and adverse pregnancy, neonatal and maternal outcomes and the proportion of confirmed cases of SARS-CoV-2 infection in neonates associated with maternal COVID-19. Methods and analysis Prospective cohort study using national linked data sets. We will include all women in Scotland, UK, who were pregnant on or became pregnant after, 1 March 2020 (the date of the first confirmed case of SARS-CoV-2 infection in Scotland) and all births in Scotland from 1 March 2020 onwards. Individual-level data will be extracted from data sets containing details of all livebirths, stillbirth, terminations of pregnancy and miscarriages and ectopic pregnancies treated in hospital or attending general practice. Records will be linked within the Early Pandemic Evaluation and Enhanced Surveillance of COVID-19 (EAVE II) platform, which includes primary care records, virology and serology results and details of COVID-19 Community Hubs and Assessment Centre contacts and deaths. We will perform analyses using definitions for confirmed, probable and possible COVID-19 and report serology results (where available). Outcomes will include congenital anomaly, miscarriage, stillbirth, termination of pregnancy, preterm birth, neonatal infection, severe maternal disease and maternal deaths. We will perform descriptive analyses and appropriate modelling, adjusting for demographic and pregnancy characteristics and the presence of comorbidities. The cohort will provide a platform for future studies of the effectiveness and safety of therapeutic interventions and immunisations for COVID-19 and their effects on childhood and developmental outcomes. Ethics and dissemination COVID-19 in Pregnancy in Scotland is a substudy of EAVE II(, which has approval from the National Research Ethics Service Committee. Findings will be reported to Scottish Government, Public Health Scotland and published in peer-reviewed journals.